1. Protein Tyrosine Kinase/RTK
  2. VEGFR


VEGFRs (vascular endothelial growth factor receptors) are tyrosine kinase receptors responsible for binding with VEGF to initiate signal cascades that stimulate angiogenesis among other effects. VEGFRs convey signals to other signal transduction effectors via autophosphorylation of specific residues in its structure. VEGFR subtypes are numbered 1,2,3. The VEGFRs are a family of tyrosine kinase receptors on the surface of different cells depending on family identity. VEGFR-1 is expressed on haematopoietic stem cells, monocytes, and vascular endothelial cells. VEGFR-2 is expressed on vascular endothelial cells and lymphatic endothelial cells, while VEGFR-3 is only expressed on lymphatic endothelial cells. VEGFRs are an important target for pharmaceutical drugs treating cancer.

VEGFR Related Products (90):

Cat. No. Product Name Effect Purity
  • HY-10201
    Sorafenib Inhibitor 99.83%
    Sorafenib is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
  • HY-10331
    Regorafenib Inhibitor 99.63%
    Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
  • HY-10201A
    Sorafenib Tosylate Inhibitor 99.73%
    Sorafenib tosylate is a potent multikinase inhibitor, with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
  • HY-50904
    BIBF 1120 Inhibitor 99.75%
    BIBF 1120 is a potent triple angiokinase inhibitor for VEGFR1/2/3FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
  • HY-10374
    SU5416 Inhibitor 99.93%
    Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR.
  • HY-B1305
    Chloropyramine hydrochloride Inhibitor
    Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of VEGFR-3 and FAK.
  • HY-101931
    hVEGF-IN-1 98.31%
    hVEGF-IN-1 represses human VEGF-A translation and shows antitumor activity.
  • HY-19326
    SU1498 Inhibitor 99.46%
    SU1498 is a selective inhibitor of the VEGFR2; inhibits Flk-1 with an IC50 of value of 700 nM.
  • HY-12047
    Ponatinib Inhibitor 98.96%
    Ponatinib is a potent, orally available multi-targeted kinase inhibitor with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
  • HY-10255A
    Sunitinib Inhibitor 99.56%
    Sunitinib is a potent tyrosine kinase inhibitor targeting VEGFR2 and PDGFRβ with IC50 of 80 nM and 2 nM, respectively.
  • HY-13016
    Cabozantinib Inhibitor 99.92%
    Cabozantinib is a potent multiple RTKs inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
  • HY-10260
    Vandetanib Inhibitor 99.89%
    Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM.
  • HY-10981
    Lenvatinib Inhibitor 99.69%
    E7080 (Lenvatinib) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β.
  • HY-10255
    Sunitinib Malate Inhibitor 99.47%
    Sunitinib Malate is a potent tyrosine kinase inhibitor targeting VEGFR2 and PDGFRβ with IC50 of 80 nM and 2 nM, respectively.
  • HY-13342
    Apatinib Inhibitor 99.76%
    Apatinib is a selective VEGFR2 inhibitor with IC50 of 1 nM.
  • HY-10208
    Pazopanib Inhibitor 99.44%
    Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
  • HY-10338
    Foretinib Inhibitor 99.81%
    Foretinib (GSK1363089; XL880; EXEL-2880; GSK089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM.
  • HY-10407
    SU 5402 Inhibitor 99.23%
    SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.
  • HY-15391
    E-3810 Inhibitor 98.24%
    E-3810 is a novel dual inhibitor of the VEGF and FGF receptors, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50 of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.
  • HY-10065
    Axitinib Inhibitor 99.77%
    Axitinib is a receptor kinase inhibitor of VEGFRs and, at higher doses, PDGFRs (IC50=0.1 nM for VEGFR1, 0.2 nM for VEGFR2, 0.1-0.3 nM for VEGFR3, and 1.6 nM for PDGFRβ).